Novartis (NYSE:NVS)‘s stock had its “neutral” rating reissued by equities researchers at JPMorgan Chase in a research note issued to investors on Thursday.

Several other research firms have also recently issued reports on NVS. Deutsche Bank reissued a “neutral” rating on shares of Novartis in a research note on Tuesday, April 10th. ValuEngine cut Novartis from a “hold” rating to a “sell” rating in a research note on Wednesday, May 2nd. Five equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $89.81.

Shares of Novartis stock opened at $77.60 on Thursday. Novartis has a one year low of $77.85 and a one year high of $78.03. The company has a market cap of $181.53 billion, a P/E ratio of 16.13, a P/E/G ratio of 1.76 and a beta of 0.76. The company has a current ratio of 1.17, a quick ratio of 0.91 and a debt-to-equity ratio of 0.33.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Thursday, April 19th. The company reported $1.28 EPS for the quarter, topping the Zacks’ consensus estimate of $1.25 by $0.03. Novartis had a return on equity of 16.23% and a net margin of 16.04%. The firm had revenue of $12.69 billion for the quarter, compared to the consensus estimate of $12.45 billion. During the same quarter last year, the business posted $1.13 earnings per share. The firm’s revenue was up 10.0% compared to the same quarter last year. research analysts predict that Novartis will post 5.28 earnings per share for the current year.

In other news, major shareholder Institutes For Biomed Novartis acquired 766,666 shares of the company’s stock in a transaction dated Monday, April 23rd. The stock was acquired at an average cost of $15.00 per share, with a total value of $11,499,990.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.01% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Garland Capital Management Inc. grew its stake in shares of Novartis by 1.0% in the fourth quarter. Garland Capital Management Inc. now owns 52,233 shares of the company’s stock valued at $4,385,000 after buying an additional 535 shares in the last quarter. Tradition Capital Management LLC grew its stake in shares of Novartis by 0.9% in the fourth quarter. Tradition Capital Management LLC now owns 69,381 shares of the company’s stock valued at $5,825,000 after buying an additional 652 shares in the last quarter. Commerce Bank grew its stake in shares of Novartis by 2.4% in the fourth quarter. Commerce Bank now owns 28,004 shares of the company’s stock valued at $2,352,000 after buying an additional 664 shares in the last quarter. Abbot Financial Management Inc. grew its stake in shares of Novartis by 2.5% in the first quarter. Abbot Financial Management Inc. now owns 28,769 shares of the company’s stock valued at $2,326,000 after buying an additional 700 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. grew its stake in shares of Novartis by 1.6% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 45,425 shares of the company’s stock valued at $3,814,000 after buying an additional 716 shares in the last quarter. 10.82% of the stock is owned by institutional investors and hedge funds.

About Novartis

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.